A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, 4-PERIOD, CROSSOVER, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF-07293893 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS
Latest Information Update: 12 Apr 2025
At a glance
- Drugs PF-07293893 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Pfizer
Most Recent Events
- 29 Mar 2024 Status changed from recruiting to completed.
- 21 Aug 2023 Planned End Date changed from 6 Feb 2024 to 22 Mar 2024.
- 21 Aug 2023 Planned primary completion date changed from 6 Feb 2024 to 22 Mar 2024.